What Happened

Eli Lilly and Company announced Phase 1 data for its investigational type II JAK2 inhibitor AJ1-11095 in myelofibrosis. The results, to be presented at the 2026 EHA Annual Meeting, showed significant spleen volume reduction, symptom improvement, and a manageable safety profile.

Who Is Affected

This impacts myelofibrosis patients who have failed prior type I JAK2 inhibitor treatments. The trial enrolled 23 heavily pretreated patients across multiple myelofibrosis subtypes and driver mutations.

Market Impact

• Extends Lilly's pipeline into hematologic malignancies.
• Potential new treatment option for resistant myelofibrosis patients.
• Highlights Lilly's continued focus on innovative therapies.

What to Watch

Monitor durability of responses, expansion cohort outcomes, and how this hematology asset complements Lilly's existing metabolic and immunology franchises. Future updates will be critical for assessing long-term efficacy and safety.